Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Endometrial Cancer
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
Related Questions
How would you treat recurrent endometrial carcinoma with a presentation of inguinal and external iliac adenopathy?
How do you manage a FIGO stage IB dedifferentiated endometrial carcinoma that is MMR deficient and p53 wt?
How would you sequence adjuvant chemo-immunotherapy (paclitaxel/carbo/pembro or paclitaxel/carbo/dostarlimab) with EBRT and vaginal cuff brachytherapy in advanced uterine cancer that meets clinical criteria for both EBRT and chemo-IO?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
Do you perform routine pelvic exams on patients undergoing active treatment for gynecologic cancer without GYN symptoms?
Following surgical staging, what adjuvant therapy would you recommend for stage IB grade 3 endometrioid endometrial carcinoma with +LVSI?
Would you treat with extended field pelvic radiation for a patient with FIGO IIIC1 endometrial cancer who was found with isolated tumor cells (ITCs) on a single paraaortic sentinel lymph node?
Would you consider trying Pembrolizumab + Lenvatinib after progression on first-line Carboplatin + Paclitaxel + Immunotherapy for metastatic endometrial cancer?
What adjuvant treatment would you recommend for a patient with FIGO 2023 IIIB2 endometrioid endometrial adenocarcinoma (Grade 3, p53mut, MMR proficient), metastatic to the uterine serosa, bilateral ovaries, and anterior peritoneal reflection?
